… TKI resistance evolves dynamically under the selective pressure exerted by each targeted
therapy. In some (but not all) cases, the evolution of TKI resistance can lead to significant …

… Cancer may be more like the mythical, multiheaded Hydra battled by Hercules because
of its ability to resist targeted therapies through evolution and tumor heterogeneity. …

… suggest that, although resistance to targeted therapies remains a challenge to modern
oncology, deeper understanding of drug-resistant tumors and the epigenetic drivers of therapy …

… of resistance. We provide formulas for the probability that resistant cells exist at the start of
therapy, … For parameter values that are typical for single targeted therapies, it is expected that …

… mechanisms to resist the targeting agent. … resistance. We attempt to summarize the gap in
knowledge in understanding acquired resistance to early-phase lung cancer targeted therapy …

… We need to know more about how CAFs form multi-faceted support systems for drug-resisting …
CAF-directed stromal-targeting agents [166] in the arsenal of targeted therapy options. …

… Evidence is provided for some rationalizations about treatment paradigms for targeted
therapy–resistant NSCLC, with a focus on extra cranial progression that may benefit from radiation…

… restored trastuzumab sensitivity in our in vitro model of resistance, demonstrating the potential
importance of this pathway as a therapeutic target in trastuzumab-resistant breast cancer. …

… how melanomas resist therapy. … affect targeted therapy. Overall, this review is designed to
draw attention to the role that the tumor microenvironment plays in driving therapy resistance. …

… cancer such as RNAi, which in combination with traditional therapies could silence genes
that are involved in the drug resistance. These genes may either be motivators of apoptosis …